MCPP
Discover related
3 sources
Collated from PsychonautWiki, TripSit, Pharmacology. Where sources differ (e.g. dosing), Compare shows them side by side.
Also known as mCPPPW
A phenylpiperazine stimulant first developed in the 1970s before being sold in the RC market, often mislabelled as MDMA. Said to have very unpleasant effects such as anxiogenesis and headaches.TS
Oral
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 15 mg | 20–50 mg | 50–120 mg | 120–150 mg | 150 mg+ |
| Onset | 20–60 minutes |
|---|---|
| Come-up | 20–60 minutes |
| Peak | 2–4 hours |
| Offset | 3–8 hours |
Unsafe interactionsPW
Caution / uncertainPW
🧬 Receptor activityPH
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1B | — | Ki 4.4 nM | CHEMBL | Target5-hydroxytryptamine receptor 1B Action— AffinityKi 4.4 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 2C | — | Ki 7.943 nM | CHEMBL | Target5-hydroxytryptamine receptor 2C Action— AffinityKi 7.943 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 2B | — | Ki 10 nM | CHEMBL | Target5-hydroxytryptamine receptor 2B Action— AffinityKi 10 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 1A | — | Ki 23 nM | CHEMBL | Target5-hydroxytryptamine receptor 1A Action— AffinityKi 23 nM SourceCHEMBL |
| Serotonin 1 (5-HT1) receptor | — | Ki 25 nM | CHEMBL | TargetSerotonin 1 (5-HT1) receptor Action— AffinityKi 25 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 2A | — | Ki 25.12 nM | CHEMBL | Target5-hydroxytryptamine receptor 2A Action— AffinityKi 25.12 nM SourceCHEMBL |
| Serotonin 2 (5-HT2) receptor | — | Ki 40 nM | CHEMBL | TargetSerotonin 2 (5-HT2) receptor Action— AffinityKi 40 nM SourceCHEMBL |
| Serotonin 3 (5-HT3) receptor | — | Ki 62 nM | CHEMBL | TargetSerotonin 3 (5-HT3) receptor Action— AffinityKi 62 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 7 | — | Ki 163 nM | CHEMBL | Target5-hydroxytryptamine receptor 7 Action— AffinityKi 163 nM SourceCHEMBL |
| Adrenergic receptor alpha-1 | — | Ki 236 nM | CHEMBL | TargetAdrenergic receptor alpha-1 Action— AffinityKi 236 nM SourceCHEMBL |
| Sodium-dependent serotonin transporter | — | Ki 271 nM | CHEMBL | TargetSodium-dependent serotonin transporter Action— AffinityKi 271 nM SourceCHEMBL |
| D(1A) dopamine receptor | — | Ki 1000 nM | CHEMBL | TargetD(1A) dopamine receptor Action— AffinityKi 1000 nM SourceCHEMBL |
| D(2) dopamine receptor | — | Ki 1000 nM | CHEMBL | TargetD(2) dopamine receptor Action— AffinityKi 1000 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 6 | — | Ki 1748 nM | CHEMBL | Target5-hydroxytryptamine receptor 6 Action— AffinityKi 1748 nM SourceCHEMBL |
| Sigma non-opioid intracellular receptor 1 | — | Ki 6150 nM | CHEMBL | TargetSigma non-opioid intracellular receptor 1 Action— AffinityKi 6150 nM SourceCHEMBL |
| 5-hydroxytryptamine receptor 5A | — | Ki 8700 nM | CHEMBL | Target5-hydroxytryptamine receptor 5A Action— AffinityKi 8700 nM SourceCHEMBL |
Pharmacokinetics
Half-lifePH
Groups of 5 male Wistar rats were dosed orally with 5 mg/kg of either (14)C-Mecoprop-P-EHE (radiochemical purity: 99.6%, spec. act.: 145.37 uCi/mg) (Groups A and C) or (14)C-Mecoprop-P-DMA (radiochemical purity (based on the acid): 99.8%, spec. act.: 114.79 uCi/mg) (Groups B and D). ... The half-life for elimination was 8.36 and 6.61 hours for Groups A and B, respectively. ...
/In/ two cases of serious intoxication with phenoxy herbicides (MCPP) ... The plasma half-life was about 17 hr. MCPP plasma elimination probably follows first-order kinetics.
AbsorptionPH
Male and female Wistar rats with dosed orally with (14)C-Mecoprop-P (radiochemical purity: 99.5%, purity: 98.6%; spec. act.: 138.8 uCi/mg). Five rats/sex were dosed with 5 (Groups A, B, D) or 100 mg/kg (Groups C and E). The rats in Group B received 14 doses of unlabeled Mecoprop-P (purity: 99.8%) at 5 mg/kg/day prior to being dosed with the radiolabeled material. In addition,12 rats/sex were dosed with 5 mg/kg (Group F). In Groups A, B and C, urine and feces were collected for 7 days. Expired air was collected from two males in Group C. In Groups D and E, blood samples were collected for 7 days. In Group F, four animals/sex/timepoint were euthanized at 0.5, 3 and 6 hours after dosing. Absorption of the administered dose ranged from 82.92 to 100.47% with the absorption minimally reduced in the repeated dosing regimen and at the higher dosing level (males: A. 100.47%, B. 94.58%, C. 92.34%; females: A. 94.62%, B. 92.07%, C. 82.92%). Excretion was predominantly via the urine with the percentage of the total dose recovered in the urine and cage wash ranging from 79.74 to 100.06%. In Group A, 95.29 and 92.29% of the administered dose was collected in the urine and the cage wash within the first 24 hours for males and females, respectively. Repeated dosing reduced the amount collected in the urine and the cage wash during the first 24 hours to 88.97 and 86.46% for males and females, respectively. Likewise, at the 100 mg/kg dosing level, the percentage collected in the urine and the cage wash during the first 24 hours was reduced to 61.18 and 56.78% for males and females, respectively. The total radiolabel recovered in the feces ranged from 3.56 to 12.52% of the administered dose. No radiolabeled material was recovered in the expired air due to the positioning of the label on the phenyl ring. Radiolabel in the tissues and organs 7 days after dosing was predominantly in the fat followed by the skin, adrenals, kidneys and liver. Maximal levels of radioactivity were recovered from the various tissues and organs assayed within 3 hours of dosing (Group F). In the plasma pharmacokinetic analysis, Tmax values were 1.8 and 2.7 hours for males and females, respectively in Group D and 4.2 hours in Group E. /The half-life/ for elimination was 6.35 and 4.23 hours in Group D and 7.89 and 7.79 hours in Group E for males and females, respectively. ... /Mecoprop-p/
Groups of 5 male Wistar rats were dosed orally with 5 mg/kg of either (14)C-Mecoprop-P-EHE (radiochemical purity: 99.6%, spec. act.: 145.37 uCi/mg) (Groups A and C) or (14)C-Mecoprop-P-DMA /(dimethylamine salt)/ (radiochemical purity (based on the acid): 99.8%, spec. act.: 114.79 uCi/mg) (Groups B and D). In Groups A and B (plasma pharmacokinetic study), blood samples were collected for 7 days. In Groups C and D, urine and feces were collected for 7 days. Expired air was collected for 48 hours. In the plasma pharmacokinetic analysis, Tmax values were 3.6 and 2 hr for Groups A and B, respectively. The half-life for elimination was 8.36 and 6.61 hours for Groups A and B, respectively. Absorption of the administered dose was at least 83.26 and 97.11% for Groups C and D, respectively (the total residual radiolabel in the tissues was not determined). Excretion was predominantly via the urine with the percentage of the total dose recovered in the urine 83.26 and 97.11%. In Groups C and D, respectively, 79.73 and 93.52% of the administered dose (calculated by the reviewer) was collected in the urine and the cage wash within the first 24 hours. The total radiolabel recovered in the feces was 3.29 and 4.68% of the administered dose for Groups C and D, respectively. No radiolabeled material was recovered in the expired air due to the positioning of the label on the phenyl ring. Radiolabel in the tissues and organs 7 days after dosing was largely limited to the skin and fat. The only metabolite identified in the study was hydroxymethyl-Mecoprop-P. Overall, unaltered test material and the hydroxylated metabolite constituted 96% of the recovered radiolabel in the first 48 hours after dosing. The parent material constituted 72.91 and 70.68% and the metabolite was 23.13 and 25.26% of the administered dose for Groups C and D, respectively.
MetabolismPH
MCPP-p-DMAS (14)C-MCPP-p DMAS was incubated in vitro with rat plasma, stomach content, gastro-intestinal tract (GIT) or postmitochondrial liver fraction (S9) for 30 minutes. All incubated extracts were subjected to HPLC analysis. Results indicated that all of the administered (14)C-MCPP-p DMAS in plasma, stomach contents, gastro-intestinal tract and liver (S9) was present as the ionized form of (14)C-MCPP-p.
Male and female Wistar rats with dosed orally with (14)C-Mecoprop-P (radiochemical purity: 99.5%, purity: 98.6%; spec. act.: 138.8 uCi/mg). Five rats/sex were dosed with 5 (Groups A, B, D) or 100 mg/kg (Groups C and E). The rats in Group B received 14 doses of unlabeled Mecoprop-P (purity: 99.8%) at 5 mg/kg/day prior to being dosed with the radiolabeled material. In addition,12 rats/sex were dosed with 5 mg/kg (Group F). ... The only metabolite identified in the study was hydroxymethyl-Mecoprop-P. A greater percentage of this metabolite was recovered in the urine of the males. Overall, unaltered test material and the hydroxylated metabolite constituted 92.29 to 95.34% of the recovered radiolabel in the urine in the first 48 hours after dosing. For the males, the parent material was 52.17 to 67.08% and the metabolite was 28.26 to 41.39% of the administered dose. For the females these values ranged from 84.31 to 90.03% for the parent compound and 5.16 to 10.25% for the metabolite. /Mecoprop-p/
The dissociation of Mecoprop-p-DMA salt into Mecoprop-P acid and dimethyl amine was examined in various in vitro biological test systems. (14)C-Mecoprop-p-DMA was formed by mixing (14)C-Mecoprop-p acid (radiochemical purity: 99.5%, chemical purity: 98.6%, specific activity: 138.92 uCi/mg) with a dimethylamine solution. The test material was incubated with plasma (I), stomach contents (II), the gastrointestinal tract (III) and liver S9 fraction (IV) derived from male Wistar rats. The concentrations of the test material in the incubations were 0.1 (I), 5 (II), 0.35 (III) and 0.1 (IV) mg/mL. The samples were incubated for 30 minutes at 37o C. Study results indicated that the test material had largely dissociated into Mecoprop-P acid and DMA. It was not apparent from these results whether the dissociation may have been wholly or partially mediated enzymatically.
In ...plants, degradation of the side-chain to 2-methyl-4-chlorophenol, ring hydroxylation and ring opening.
CDDs are absorbed through oral, inhalation, and dermal routes of exposure. CDDs are carried in the plasma by serum lipids and lipoproteins, distributing mainly to the liver and adipose tissue. CDDs are very slowly metabolized by the microsomal monooxygenase system to polar metabolites that can undergo conjugation with glucuronic acid and glutathione. They may increase the rate of their own metabolism by inducing CDDs induce both phase I and phase II enzymes. The major routes of excretion of CDDs are the bile and the feces, though smaller amounts are excreted in the urine and via lactation. (L177)
Plan a dose of MCPP
Loading the fact-sheet…
Logging a dose needs somewhere to keep it. Start a free session — no signup; it and everything in it expire in 7 days.
External links
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.